OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
July 16, 2021
The GMP facility is designed to maximize bioprocessing efficiency of newborn stem cells and manufacturing at scale.
July 09, 2021
GlaxoSmithKline and Alector have partnered to co-develop two mAbs for a range of neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease.
July 03, 2021
The ever-increasing complexity of biotherapeutic molecules presents unique analytical challenges for developers.
The future pipeline of complex novel biotherapeutics will require new approaches to analytical assessment.
July 01, 2021
Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.
June 30, 2021
Corbus Pharmaceuticals has licensed two integrin-targeting mAbs, expanding its therapeutics pipeline into inflammatory, fibrotic, and metabolic diseases as well as cancer.
June 25, 2021
AbbVie has exercised its right to acquire TeneoOne, along with its lead immunotherapeutic asset for the potential treatment of multiple myeloma.
FDA has granted breakthrough therapy designation to donanemab, Eli Lilly and Co.’s investigational antibody treatment for Alzheimer’s disease.
June 24, 2021
The companies have entered into an agreement to develop processes for a novel immunotherapy protein.
June 18, 2021
GlaxoSmithKline and iTeos Therapeutics enter into a development and commercialization collaboration worth up to $2.08 billion for a new therapeutic anti-cancer mAb candidate.